239 related articles for article (PubMed ID: 27657335)
21. Characterization of the West Nile virus protease substrate specificity and inhibitors.
Mueller NH; Yon C; Ganesh VK; Padmanabhan R
Int J Biochem Cell Biol; 2007; 39(3):606-14. PubMed ID: 17188926
[TBL] [Abstract][Full Text] [Related]
22. Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro.
Yusof R; Clum S; Wetzel M; Murthy HM; Padmanabhan R
J Biol Chem; 2000 Apr; 275(14):9963-9. PubMed ID: 10744671
[TBL] [Abstract][Full Text] [Related]
23. Serotype-specific structural differences in the protease-cofactor complexes of the dengue virus family.
Chandramouli S; Joseph JS; Daudenarde S; Gatchalian J; Cornillez-Ty C; Kuhn P
J Virol; 2010 Mar; 84(6):3059-67. PubMed ID: 20042502
[TBL] [Abstract][Full Text] [Related]
24. The Transactions of NS3 and NS5 in Flaviviral RNA Replication.
Tay MYF; Vasudevan SG
Adv Exp Med Biol; 2018; 1062():147-163. PubMed ID: 29845531
[TBL] [Abstract][Full Text] [Related]
25. Design and docking studies of peptide inhibitors as potential antiviral drugs for dengue virus ns2b/ns3 protease.
Velmurugan D; Mythily U; Rao K
Protein Pept Lett; 2014; 21(8):815-27. PubMed ID: 23855663
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous uncoupled expression and purification of the Dengue virus NS3 protease and NS2B co-factor domain.
Shannon AE; Chappell KJ; Stoermer MJ; Chow SY; Kok WM; Fairlie DP; Young PR
Protein Expr Purif; 2016 Mar; 119():124-9. PubMed ID: 26647367
[TBL] [Abstract][Full Text] [Related]
27. Use of parallel validation high-throughput screens to reduce false positives and identify novel dengue NS2B-NS3 protease inhibitors.
Tomlinson SM; Watowich SJ
Antiviral Res; 2012 Feb; 93(2):245-252. PubMed ID: 22193283
[TBL] [Abstract][Full Text] [Related]
28. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target.
Lescar J; Luo D; Xu T; Sampath A; Lim SP; Canard B; Vasudevan SG
Antiviral Res; 2008 Nov; 80(2):94-101. PubMed ID: 18674567
[TBL] [Abstract][Full Text] [Related]
29. A Proline-Rich N-Terminal Region of the Dengue Virus NS3 Is Crucial for Infectious Particle Production.
Gebhard LG; Iglesias NG; Byk LA; Filomatori CV; De Maio FA; Gamarnik AV
J Virol; 2016 Jun; 90(11):5451-61. PubMed ID: 27009958
[TBL] [Abstract][Full Text] [Related]
30. In vitro determination of dengue virus type 2 NS2B-NS3 protease activity with fluorescent peptide substrates.
Khumthong R; Angsuthanasombat C; Panyim S; Katzenmeier G
J Biochem Mol Biol; 2002 Mar; 35(2):206-12. PubMed ID: 12297031
[TBL] [Abstract][Full Text] [Related]
31. A comparative biochemical analysis of the NS2B(H)-NS3pro protease complex from four dengue virus serotypes.
Iempridee T; Thongphung R; Angsuthanasombat C; Katzenmeier G
Biochim Biophys Acta; 2008; 1780(7-8):989-94. PubMed ID: 18439431
[TBL] [Abstract][Full Text] [Related]
32. Structure-guided mutagenesis of active site residues in the dengue virus two-component protease NS2B-NS3.
Salaemae W; Junaid M; Angsuthanasombat C; Katzenmeier G
J Biomed Sci; 2010 Aug; 17(1):68. PubMed ID: 20735839
[TBL] [Abstract][Full Text] [Related]
33. Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain.
Arias CF; Preugschat F; Strauss JH
Virology; 1993 Apr; 193(2):888-99. PubMed ID: 8460492
[TBL] [Abstract][Full Text] [Related]
34. Impaired heterologous protein-protein interaction is an essential cause for non-viability of WNV/DENV recombinants.
Lei Y; Takeda K; Yu L
Virology; 2018 Nov; 524():140-150. PubMed ID: 30195251
[TBL] [Abstract][Full Text] [Related]
35. 3D-QSAR pharmacophore-based virtual screening, molecular docking and molecular dynamics simulation toward identifying lead compounds for NS2B-NS3 protease inhibitors.
Luo PH; Zhang XR; Huang L; Yuan L; Zhou XZ; Gao X; Li LS
J Recept Signal Transduct Res; 2017 Oct; 37(5):481-492. PubMed ID: 28758854
[TBL] [Abstract][Full Text] [Related]
36. Co-refolding of a functional complex of Dengue NS3 protease and NS2B co-factor domain and backbone resonance assignment by solution NMR.
Woestenenk E; Agback P; Unnerståle S; Henderson I; Agback T
Protein Expr Purif; 2017 Dec; 140():16-27. PubMed ID: 28751017
[TBL] [Abstract][Full Text] [Related]
37. Identification of novel thiadiazoloacrylamide analogues as inhibitors of dengue-2 virus NS2B/NS3 protease.
Liu H; Wu R; Sun Y; Ye Y; Chen J; Luo X; Shen X; Liu H
Bioorg Med Chem; 2014 Nov; 22(22):6344-52. PubMed ID: 25438757
[TBL] [Abstract][Full Text] [Related]
38. In silico evaluation of inhibitory potential of triterpenoids from Azadirachta indica against therapeutic target of dengue virus, NS2B-NS3 protease.
Dwivedi VD; Tripathi IP; Mishra SK
J Vector Borne Dis; 2016; 53(2):156-61. PubMed ID: 27353586
[TBL] [Abstract][Full Text] [Related]
39. Proteochemometrics analysis of substrate interactions with dengue virus NS3 proteases.
Prusis P; Lapins M; Yahorava S; Petrovska R; Niyomrattanakit P; Katzenmeier G; Wikberg JE
Bioorg Med Chem; 2008 Oct; 16(20):9369-77. PubMed ID: 18824362
[TBL] [Abstract][Full Text] [Related]
40. Yellow fever virus NS3 protease: peptide-inhibition studies.
Löhr K; Knox JE; Phong WY; Ma NL; Yin Z; Sampath A; Patel SJ; Wang WL; Chan WL; Rao KRR; Wang G; Vasudevan SG; Keller TH; Lim SP
J Gen Virol; 2007 Aug; 88(Pt 8):2223-2227. PubMed ID: 17622626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
